{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:52:12Z","timestamp":1792601532481,"version":"4.5.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T00:00:00Z","timestamp":1710201600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T00:00:00Z","timestamp":1710201600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100016650","name":"Rare Diseases Clinical Research Network","doi-asserted-by":"publisher","award":["1U54AR068069\u20130"],"award-info":[{"award-number":["1U54AR068069\u20130"]}],"id":[{"id":"10.13039\/100016650","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Calcif Tissue Int"],"DOI":"10.1007\/s00223-024-01188-2","type":"journal-article","created":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T22:01:51Z","timestamp":1710280911000},"page":"805-811","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Current and Developing Pharmacologic Agents for Improving Skeletal Health in Adults with Osteogenesis Imperfecta"],"prefix":"10.1007","volume":"115","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2607-0336","authenticated-orcid":false,"given":"Winnie","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsey","family":"Nicol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Orwoll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,12]]},"reference":[{"issue":"10028","key":"1188_CR1","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1016\/S0140-6736(15)00728-X","volume":"387","author":"A Forlino","year":"2016","unstructured":"Forlino A, Marini JC (2016) Osteogenesis imperfecta. Lancet 387(10028):1657\u20131671","journal-title":"Lancet"},{"key":"1188_CR2","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1210\/clinem\/dgad035","volume":"108","author":"W Liu","year":"2023","unstructured":"Liu W et al (2023) Approach to the patient: pharmacological therapies for fracture risk reduction in adults with osteogenesis imperfecta. J Clin Endocrinol Metab 108:1787\u20131796","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"1188_CR3","first-page":"Cd005088","volume":"10","author":"K Dwan","year":"2016","unstructured":"Dwan K et al (2016) Bisphosphonate therapy for osteogenesis imperfecta. Cochrane Database Syst Rev 10(10):Cd005088","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"1188_CR4","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1359\/jbmr.2003.18.1.126","volume":"18","author":"S Adami","year":"2003","unstructured":"Adami S et al (2003) Intravenous neridronate in adults with osteogenesis imperfecta. J Bone Miner Res 18(1):126\u2013130","journal-title":"J Bone Miner Res"},{"issue":"2","key":"1188_CR5","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1359\/JBMR.051015","volume":"21","author":"G Chevrel","year":"2006","unstructured":"Chevrel G et al (2006) Effects of oral alendronate on BMD in adult patients with osteogenesis imperfecta: a 3-year randomized placebo-controlled trial. J Bone Miner Res 21(2):300\u2013306","journal-title":"J Bone Miner Res"},{"issue":"2","key":"1188_CR6","first-page":"108","volume":"66","author":"I Pav\u00f3n de Paz","year":"2019","unstructured":"Pav\u00f3n de Paz I et al (2019) Acute and long-term effects of zoledronate in adult patients with osteogenesis imperfecta. An observational Spanish study with five years of follow-up. Endocrinol Diabetes Nutr (Engl Ed) 66(2):108\u2013116","journal-title":"Endocrinol Diabetes Nutr (Engl Ed)"},{"issue":"4","key":"1188_CR7","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s00223-017-0236-9","volume":"100","author":"O Viapiana","year":"2017","unstructured":"Viapiana O et al (2017) Long-term effects of neridronate in adults with osteogenesis imperfecta: an observational three-year Italian study. Calcif Tissue Int 100(4):341\u2013347","journal-title":"Calcif Tissue Int"},{"issue":"2","key":"1188_CR8","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1007\/s00223-010-9383-y","volume":"87","author":"JR Shapiro","year":"2010","unstructured":"Shapiro JR et al (2010) Bone mineral density and fracture rate in response to intravenous and oral bisphosphonates in adult osteogenesis imperfecta. Calcif Tissue Int 87(2):120\u2013129","journal-title":"Calcif Tissue Int"},{"issue":"11","key":"1188_CR9","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.4158\/EP151184.OR","volume":"22","author":"XJ Xu","year":"2016","unstructured":"Xu XJ et al (2016) The clinical characteristics and efficacy of bisphophonates in adult patients with osteogenesis Imperfecta. Endocr Pract 22(11):1267\u20131276","journal-title":"Endocr Pract"},{"key":"1188_CR10","first-page":"509","volume-title":"Osteogenesis imperfecta a translational approach to brittle bone disease","author":"J Shapiro","year":"2014","unstructured":"Shapiro J (2014) Osteogenesis imperfecta: maintenance of adult bone health. In: Shapiro J (ed) Osteogenesis imperfecta a translational approach to brittle bone disease. Academic Press, Cambridge, pp 509\u2013518"},{"issue":"1","key":"1188_CR11","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s00198-011-1658-2","volume":"23","author":"LA Bradbury","year":"2012","unstructured":"Bradbury LA et al (2012) Risedronate in adults with osteogenesis imperfecta type I: increased bone mineral density and decreased bone turnover, but high fracture rate persists. Osteoporos Int 23(1):285\u2013294","journal-title":"Osteoporos Int"},{"issue":"5","key":"1188_CR12","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1210\/jc.2019-00221","volume":"104","author":"R Eastell","year":"2019","unstructured":"Eastell R et al (2019) Pharmacological management of osteoporosis in postmenopausal women: an endocrine society* clinical practice guideline. J Clin Endocrinol Metab 104(5):1595\u20131622","journal-title":"J Clin Endocrinol Metab"},{"issue":"22","key":"1188_CR13","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1056\/NEJMp1202623","volume":"366","author":"DM Black","year":"2012","unstructured":"Black DM et al (2012) Continuing bisphosphonate treatment for osteoporosis\u2013for whom and for how long? N Engl J Med 366(22):2051\u20132053","journal-title":"N Engl J Med"},{"issue":"12","key":"1188_CR14","doi-asserted-by":"publisher","first-page":"479","DOI":"10.3390\/jcm7120479","volume":"7","author":"T Kobayashi","year":"2018","unstructured":"Kobayashi T et al (2018) Efficacy and Safety of denosumab therapy for osteogenesis imperfecta patients with osteoporosis case series. J Clin Med 7(12):479","journal-title":"J Clin Med"},{"issue":"4","key":"1188_CR15","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s11914-017-0380-1","volume":"15","author":"AM Boyce","year":"2017","unstructured":"Boyce AM (2017) Denosumab: an emerging therapy in pediatric bone disorders. Curr Osteoporos Rep 15(4):283\u2013292","journal-title":"Curr Osteoporos Rep"},{"issue":"1","key":"1188_CR16","first-page":"76","volume":"18","author":"P Trejo","year":"2018","unstructured":"Trejo P, Rauch F, Ward L (2018) Hypercalcemia and hypercalciuria during denosumab treatment in children with osteogenesis imperfecta type VI. J Musculoskelet Neuronal Interact 18(1):76\u201380","journal-title":"J Musculoskelet Neuronal Interact"},{"issue":"19","key":"1188_CR17","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","volume":"344","author":"RM Neer","year":"2001","unstructured":"Neer RM et al (2001) Effect of parathyroid hormone (1\u201334) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344(19):1434\u20131441","journal-title":"N Engl J Med"},{"issue":"10","key":"1188_CR18","doi-asserted-by":"publisher","first-page":"4528","DOI":"10.1210\/jc.2002-020334","volume":"87","author":"JJ Body","year":"2002","unstructured":"Body JJ et al (2002) A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1\u201334)] with alendronate in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 87(10):4528\u20134535","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"1188_CR19","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1001\/jama.2016.11136","volume":"316","author":"PD Miller","year":"2016","unstructured":"Miller PD et al (2016) Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial. JAMA 316(7):722\u2013733","journal-title":"JAMA"},{"key":"1188_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2021.174409","volume":"909","author":"MB Brent","year":"2021","unstructured":"Brent MB (2021) Abaloparatide: a review of preclinical and clinical studies. Eur J Pharmacol 909:174409","journal-title":"Eur J Pharmacol"},{"issue":"2","key":"1188_CR21","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1172\/JCI71101","volume":"124","author":"ES Orwoll","year":"2014","unstructured":"Orwoll ES et al (2014) Evaluation of teriparatide treatment in adults with osteogenesis imperfecta. J Clin Invest 124(2):491\u2013498","journal-title":"J Clin Invest"},{"issue":"5","key":"1188_CR22","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1007\/s00223-013-9770-2","volume":"93","author":"D Gatti","year":"2013","unstructured":"Gatti D et al (2013) Teriparatide treatment in adult patients with osteogenesis imperfecta type I. Calcif Tissue Int 93(5):448\u2013452","journal-title":"Calcif Tissue Int"},{"issue":"2","key":"1188_CR23","doi-asserted-by":"publisher","first-page":"153","DOI":"10.11138\/ccmbm\/2017.14.1.153","volume":"14","author":"PT Leali","year":"2017","unstructured":"Leali PT et al (2017) Efficacy of teriparatide vs neridronate in adults with osteogenesis imperfecta type I: a prospective randomized international clinical study. Clin Cases Miner Bone Metab 14(2):153\u2013156","journal-title":"Clin Cases Miner Bone Metab"},{"issue":"2","key":"1188_CR24","doi-asserted-by":"publisher","first-page":"113","DOI":"10.3109\/08037059209077502","volume":"1","author":"L Hansson","year":"1992","unstructured":"Hansson L, Hedner T, Dahl\u00f6f B (1992) Prospective randomized open blinded end-point (PROBE) study. A novel design for intervention trials. Prospective randomized open blinded end-point. Blood Press 1(2):113\u2013119","journal-title":"Blood Press"},{"issue":"11","key":"1188_CR25","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2023-078164","volume":"13","author":"JD Hald","year":"2023","unstructured":"Hald JD et al (2023) Protocol of a randomised trial of teriparatide followed by zoledronic acid to reduce fracture risk in adults with osteogenesis imperfecta. BMJ Open 13(11):e078164","journal-title":"BMJ Open"},{"issue":"15","key":"1188_CR26","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","volume":"377","author":"KG Saag","year":"2017","unstructured":"Saag KG et al (2017) Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med 377(15):1417\u20131427","journal-title":"N Engl J Med"},{"issue":"1","key":"1188_CR27","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1093\/mrcr\/rxab018","volume":"6","author":"M Uehara","year":"2022","unstructured":"Uehara M et al (2022) Efficacy of romosozumab for osteoporosis in a patient with osteogenesis imperfecta: a case report. Mod Rheumatol Case Rep 6(1):128\u2013133","journal-title":"Mod Rheumatol Case Rep"},{"key":"1188_CR28","unstructured":"Glorieux, F.H., et al., Setrusumab for the Treatment of Osteogenesis Imperfecta (OI): Results from the Phase 2b ASTEROID Study. J Bone Miner Res. 36."},{"key":"1188_CR29","unstructured":"Lewiecki, E.M., (2023) Evaluating setrusumab for the treatment of osteogenesis imperfecta: phase 2 data from the phase 2\/3 ORBIT study. J Bone Miner Res. 38(2)."},{"issue":"6","key":"1188_CR30","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1038\/nm.3544","volume":"20","author":"I Grafe","year":"2014","unstructured":"Grafe I et al (2014) Excessive transforming growth factor-\u03b2 signaling is a common mechanism in osteogenesis imperfecta. Nat Med 20(6):670\u2013675","journal-title":"Nat Med"},{"issue":"3","key":"1188_CR31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0090353","volume":"9","author":"JC Morris","year":"2014","unstructured":"Morris JC et al (2014) Phase I study of GC1008 (fresolimumab): a human anti-transforming growth factor-beta (TGF\u03b2) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma. PLoS ONE 9(3):e90353","journal-title":"PLoS ONE"},{"issue":"5","key":"1188_CR32","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1016\/j.ekir.2017.03.011","volume":"2","author":"F Vincenti","year":"2017","unstructured":"Vincenti F et al (2017) A phase 2, double-blind, placebo-controlled, randomized study of fresolimumab in patients with steroid-resistant primary focal segmental glomerulosclerosis. Kidney Int Rep 2(5):800\u2013810","journal-title":"Kidney Int Rep"},{"issue":"7","key":"1188_CR33","doi-asserted-by":"publisher","first-page":"2795","DOI":"10.1172\/JCI77958","volume":"125","author":"LM Rice","year":"2015","unstructured":"Rice LM et al (2015) Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients. J Clin Invest 125(7):2795\u20132807","journal-title":"J Clin Invest"},{"issue":"7","key":"1188_CR34","doi-asserted-by":"publisher","first-page":"e152571","DOI":"10.1172\/JCI152571","volume":"132","author":"IW Song","year":"2022","unstructured":"Song IW et al (2022) Targeting TGF-\u03b2 for treatment of osteogenesis imperfecta. J Clin Invest 132(7):e152571","journal-title":"J Clin Invest"},{"key":"1188_CR35","doi-asserted-by":"publisher","first-page":"11505","DOI":"10.1038\/ncomms11505","volume":"7","author":"M Florio","year":"2016","unstructured":"Florio M et al (2016) A bispecific antibody targeting sclerostin and DKK-1 promotes bone mass accrual and fracture repair. Nat Commun 7:11505","journal-title":"Nat Commun"},{"issue":"11","key":"1188_CR36","doi-asserted-by":"publisher","first-page":"2610","DOI":"10.1002\/jbmr.472","volume":"26","author":"X Li","year":"2011","unstructured":"Li X et al (2011) Dickkopf-1 regulates bone formation in young growing rodents and upon traumatic injury. J Bone Miner Res 26(11):2610\u20132621","journal-title":"J Bone Miner Res"},{"issue":"3","key":"1188_CR37","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1111\/bjh.13056","volume":"167","author":"SP Iyer","year":"2014","unstructured":"Iyer SP et al (2014) A Phase IB multicentre dose-determination study of BHQ880 in combination with anti-myeloma therapy and zoledronic acid in patients with relapsed or refractory multiple myeloma and prior skeletal-related events. Br J Haematol 167(3):366\u2013375","journal-title":"Br J Haematol"},{"issue":"1","key":"1188_CR38","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.265","volume":"11","author":"A Infante","year":"2021","unstructured":"Infante A et al (2021) Reiterative infusions of MSCs improve pediatric osteogenesis imperfecta eliciting a pro-osteogenic paracrine response: TERCELOI clinical trial. Clin Transl Med 11(1):e265","journal-title":"Clin Transl Med"}],"container-title":["Calcified Tissue International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-024-01188-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00223-024-01188-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-024-01188-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T13:04:23Z","timestamp":1732885463000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00223-024-01188-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,12]]},"references-count":38,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1188"],"URL":"https:\/\/doi.org\/10.1007\/s00223-024-01188-2","relation":{},"ISSN":["1432-0827"],"issn-type":[{"value":"1432-0827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,12]]},"assertion":[{"value":"20 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Winnie Liu has nothing to disclose. Lindsey Nicol receives consulting fees from Egetis and Ultragenyx. Eric Orwoll receives consulting fees from Ultragenyx, Angitia, and Amgen.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}